间充质干细胞外泌体在骨肉瘤治疗中的研究进展  

Research Progress of Mesenchymal Stem Cell-Derived Exosomes in Treatment of Osteosarcoma

作　　者：王福财 刘卓晟 WANG Fucai;LIU Zhuosheng(College of Medicine,Huaqiao University,Quanzhou 362021,China)

机构地区：[1]华侨大学医学院,福建泉州362021

出　　处：《华侨大学学报(自然科学版)》2025年第1期1-13,共13页Journal of Huaqiao University(Natural Science)

基　　金：国家自然科学基金资助项目(81860354,81060273);江西省青年科学基金资助项目(20132BAB215017)。

摘　　要：阐述间充质干细胞外泌体(MSC-Exos)在骨肉瘤(OS)治疗中的研究进展。通过查阅近年的相关文献,综述OS的研究现状、发病机制和潜在治疗靶点,MSC-Exos的生物学特性和功能,以及MSC-Exos在OS的靶向治疗、肿瘤耐药性和作为药物递送载体等方面的研究进展。结果表明:MSC-Exos作为一种新兴的生物治疗剂,在OS治疗领域具有广阔的应用前景。This review is to elucidate the research progress of mesenchymal stem cell-derived exosomes(MSC-Exos)in the treatment of osteosarcoma(OS).By reviewing recent relevant literature,the current status,pathogenesis and potential therapeutic targets of OS,the biological characteristics and functions of MSC-Exos,as well as the research progress of MSC-Exos in OS targeted therapy,tumor drug resistance and as a drug delivery carrier are summarized.The results show that MSC-Exos,as a novel biological therapeutic agent,has broad application prospects in OS treatment.

关 键 词：间充质干细胞 外泌体 骨肉瘤 靶向治疗 肿瘤耐药性 

分 类 号：R738.1[医药卫生—肿瘤]